Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.

Thomas L Frandsen, Jonas Abrahamsson, Birgitte Lausen, Kim Vettenranta, Mats Heyman, Michael Behrentz, Anders Castor, Peder S Wehner, Britt-Marie Frost, Elisabeth W Andersen, Kjeld Schmiegelow

Research output: Contribution to journalArticlepeer-review

9 Citations (SciVal)

Abstract

This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2) , ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.
Original languageEnglish
Pages (from-to)244-247
JournalBritish Journal of Haematology
Volume155
DOIs
Publication statusPublished - 2011

Subject classification (UKÄ)

  • Hematology

Fingerprint

Dive into the research topics of 'Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.'. Together they form a unique fingerprint.

Cite this